Due to the instability of PSA as a result of an equilibrium between its free and complexed form in vivo, its usage as a biomarker is now being limited for PCa diagnosis, despite being one of the first US Food and Drug approve (FDA) biomarker. The gene discussed is KLK3; the disease is posterior cortical atrophy.